



## מגוון הדיאטות- מה כן כדאי לקחת ללב

RD PhD קרן הרשקופ מנהלת המחלקה לתזונה ודיאטה המרכז הרפואי שערי צדק שיקום לב נובמבר 2019

## Outline:

- The patient in rehabilitation
- Dietary trends



- The effect on heart disease and cardiometabolic risk factors
- Take home message


### The rehabilitation Patient


- A cluster of diseases
- Each patient is different



• A chance for motivational change







Sandesara, P.B. et al. J Am Coll Cardiol. 2015; 65(4):389-95.

### LYON STUDY



- Randomized secondary prevention trial
- Compared the Mediterranean diet with the western diet (AHA step1)
- 605 patients that had an MI within the prior 6 months
- Mean Follow-up 45 months
- Resulted in a reduction of 50% in recurrent MI or major secondary events


### LYON STUDY

	Mediterranean diet	<b>Control French Diet</b>	<b>∆</b> Significance
Energy	1928 kcal	2140 kcal	p< 0.001
SFA	8.3 E %	11.7 E %	p< 0.001
Oleic acid	12.9 E %	10.3 E %	p< 0.001
Linoleic acid	3.6 E %	5.3 E %	p< 0.001
α –linolenic acid	0.81 E %	0.27 E %	p< 0.001
Cholesterol	217 mg	318 mg	p< 0.001
Carbohydrates*	52.3 E %	50.8 E %	N/A
Protein	17.2 E %	16.5 E %	P=0.12
Fat	30.5 E %	32.7 E %	P=0.008
Fiber	N/A	N/A	N/A
Trans fat**	N/A	N/A	N/A

#### Diet Evidence: Secondary Prevention

#### Lyon Diet Heart Study

#### 605 patients following a myocardial infarction randomized to a Mediterranean\* or Western\*\* diet for 4 years




A Mediterranean diet reduces cardiovascular events



Helping Cardiovascular Professionals Learn. Advance. Heal, \*High in polyunsaturated fat and fiber, \*\*High in saturated fat and low in fiber

Source: De Lorgeril M et al. Circulation 1999;99:779-785





Journal of Clinical

Lipidology

Original Research

Review of current evidence and clinical recommendations on the effects of lowcarbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force

Carol F. Kirkpatrick, PhD, MPH, RDN, CLS<sup>\*</sup>, Julie P. Bolick, MS, RDN, CD, CLS, Penny M. Kris-Etherton, PhD, RDN, CLS, Geeta Sikand, MA, RDN, CLS, Karen E. Aspry, MD, MS, Daniel E. Soffer, MD, Kaye-Eileen Willard, MD, Kevin C. Maki, PhD, CLS

### Low carbohydrate diets


- A moderate –CHO diet: 26-44% of TDE or 130-225 gr/d
- A low CHO diet: 10-25% of TDE 50-130 gr/d
- A very-low CHO diet<10% of TDE <50 gr/d
- Protein and fat content is variable.
- Low and moderate diets do not result in ketosis
- Typically high in SFA and cholesterol
- The severe restriction in CHO reduces intake of vegetables, fruit, legumes and whole grain.

### Effects of low and very-low CHO diet compared to high-CHO low fat diets on cardiometabolic risk markers at 1-2 years follow-up

Cardiometabolic risk factor	Adults with overweight or obesity	Adults with overweight or obesity and T2D
Weight	<b>*</b> **	↑ ↓*
LDL-C	<b>^</b> **	<b>^</b> *
HDL-C	<b>↑</b> ***	<b>^</b> **
TG	<b>*</b> **	<b>*</b> **
HbA1c	↓*	★ ⇔ ♥**
SBP		↑ ⇔ ↓** ↑ ↓**
DBP	<b>*</b> **	<b>↑ ↓</b> **

\*NS \*\*mixed results \*\*\*significant


- The effect on weight loss is mainly in the short term
- Very-low CHO diets are difficult to maintain and are not clearly superior for weight loss
- There is a variable total-C and LDL-C response to low –CHO and very-low-CHO diets
- Compared with high-CHO low fat diets the low-CHO diets result in improvement in TG and HDL-C levels.





# PORTFOLIO DIET

An evidence-based eating plan for lower cholesterol



#### WHAT IS THE PORTFOLIO DIET?

The portfolio diet is a way of eating that evidence has shown can help lower cholesterol and your risk of heart disease. Instead of focusing on what you can't eat, the Portfolio diet is about what you can add to your menu!



A plant based dietary pattern that combines know cholesterol lowering foods


- Plant based dietary pattern first devised in the early 2000.
- A "portfolio" of 4 lowering cholesterol foods
- Each of which has approved health claim for cholesterol lowering or CVD risk reduction.

(FDA, Health Canada)

For a 2000 kcal diet:

 $\checkmark$  Nuts (42 gr)  $\checkmark$  Plant protein (50 gr)  $\checkmark$  Soluble fiber (20 gr) ✓ Plant sterol- enriched margarine (2 gr) ✓ MUFA (26% of energy) ✓ Vegan- excludes:

Meat, poultry, seafood, dairy and eggs



### Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials




Laura Chiavaroli <sup>a,b</sup>, Stephanie K. Nishi <sup>a,b</sup>, Tauseef A. Khan <sup>a,b</sup>, Catherine R. Braunstein <sup>a,b</sup>, Andrea J. Glenn <sup>a,b</sup>, Sonia Blanco Mejia <sup>a,b</sup>, Dario Rahelić <sup>f</sup>, Hana Kahleová <sup>g,h</sup>, Jordi Salas-Salvadó <sup>i,j</sup>, David J.A. Jenkins <sup>a,b,c,d,e</sup>, Cyril W.C. Kendall <sup>a,b,k,\*</sup>, John L. Sievenpiper <sup>a,b,d,e,\*</sup>

					Pooled Effect Estimates						Heterogeneity			
													hange*	
		Outcome	No. trials	N	MD (95% CI)	SMD (95% CI)		SM	D (95% CI)	P-value	12	P-value *		
									1					
	LDL	LDL-C (mmol/L)	7	439	-0.73 [-0.89, -0.56]	-3.28 [-4.00, -2.51]	-	<b>—</b>		< 0.0001	67%	0.006	-17%	
		YOUTCOMES												
	Lipids	TC (mmol/L)	7	439	-0.81 [-0.98, -0.64]	-3.53 [-4.27, -2.79]	_	*/		<0.0001	52%	0.05	-12%	
	inida	TG (mmol/L)	7	439	-0.28 [-0.42, -0.14]	-1.48 [-2.22, -0.74]		-	<b>→</b>	<0.0001	58%	0.03	-16%	
	.ipids	HDL-C (mmol/L)*	7	439	-0.01 [-0.05, 0.03]	-0.19 [-0.93, 0.56]			<b></b>	0.56	22%	0.26	-1%	
		non-HDL (mmol/L)	7	439	-0.83 [-1.03, -0.64]	-3.15 [-3.91, -2.43]	-	<b>—</b>		< 0.0001	61%	0.02	-14%	
	Apolipopro	teins												
	APO-B	3 (g/L)	7	439	-0.19 [-0.23, -0.15]	-3.52 [-4.26, -2.78]	_	<b>-</b>		< 0.0001	60%	0.02	-15%	
	Blood Press													
		SBP (mmHg)	7	439	-1.75 [-3.23, -0.26]	-0.87 [-1.61, -0.13]			<b>—</b>	0.02	0%	0.79	-1%	
		DBP (mmHg)	7	439	-1.36 [-2.33, -0.38]	-1.03 [-1.77, -0.28]			<b>—</b>	0.006	0%	0.46	-2%	
	Inflammati	on												
	CRP	mg/L)	7	435	-0.58 [-1.01, -0.15]	-1.08 [-1.88, -0.28]			<b>_</b> _	0.008	33%	0.18	-32%	
		0-year CHD Risk												
		CHD risk (%)	5	415	-1.34 [-2.19, -0.49]	-1.38 [-2.26, -0.51]		_	<b>→</b>	0.002	54%	0.07	-13%	
l V	weight	ly weight (kg)	7	439	-0.1 [-0.48, 0.27]	-0.20 [-0.95, 0.53]			<b>_</b>	0.59	0%	0.99	0%	
		1												
							-5.00	-3.00	-1.00 1.00					
								Benef	it Harm					

#### Effects of a Dietary Portfolio of Cholesterol-Lowering Foods vs Lovastatin on Serum Lipids and C-Reactive Protein

Each group n=16, 4 week follow-up


2 JAMA, July 23/30, 2003-Vol 290, No. 4 (Reprinted)



LDL-C indicates low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol. Values are expressed as mean (SE) because, with the number of participants involved, approximately twice the SE represents a significant difference.

# DASH DIET Dietary Approaches to Stop Hypertension

- Fruit
- Vegetables
- Fat free/low fat dairy products
- Whole grains
- Nuts and legumes
- Limit: saturated fat, red meat, sugar, sweets, salt and sugar based beverages.







#### Review DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses

### DATA Collection:

- CVD and CHD -systematic review and metaanalysis of prospective cohort studies
- Blood pressure and blood lipids metaanalysis of controlled studies
- Follow-up 5-24 years

#### **DASH diet and CVD outcome**

							GRADE					
										Downgrade	Upgrade	
CVD Outcome	Systematic review and meta-analysis	No. Cohort Compariso ns	No. Cases		Risk ratio [95% Cls]		Ρ	Heter nei I <sup>2</sup>	-	Risk of Bias Inconsistency Indirectness Imprecision Publication bias	Dose response Large effect size Attenuation Khuietion	of the Evidence
CVD CVD Incidence CHD	Schwingshackl et al. 2015 [13]	11	32,927	783,732	0.80 [0.76, 0.85]	•	<0.001	30%	0.16		□□□ <b>⊕⊕</b> ○	O Low
CHD Incidence	Salehi-Abargouei et al. 2013 [43]	3	7,260	144,337	0.79 [0.71, 0.88]	-	<0.001	0%	0.58			O Very Low
Stroke STROKE Incidence	Salehi-Abargouei et al. 2013 [43]	з	4,413	150,191	0.81 [0.72, 0.92]		<0.001	0%	0.91		□ □ □ <b>⊕⊕</b> O	O Low
Diabetes	Jannasch et al. 2017 [12]	5	23,612	158,408	0.82 [0.74, 0.92]		0.0005	62%	0.03			O Very Low
					0.50	1.00		1.50				
						Benefit	Harm					

#### DASH diet and Cardiometabolic risk factor

								Downgrade	
Cardiometabolic Risk Factor	Systematic review and meta- analysis	No. Trial Compariso ns	Participan ts	MD (95% CI)	SMD (95% CI)	SMD (95% CI)	Heteroge neity P I <sup>2</sup> P	Risk of Bias Inconsistency Indirectness Imprecision Publication bias	Certainty of the Evidence
Blood pres	sure								
Systolic (mmHg)	Siervo et al.	19	1,918	-5.20 [-7.00, -3.40]	-1.30 [-1.75, -0.85]	-	<0.001 76% <0.001		<b>⊕⊕⊕</b> ⊖ Moderate
Diastolic (mmHg)	2015 [11]	19	1,918	-2.60 [-3.50, -1.70]	-1.30 [-1.75, -0.85]	+	<0.001 49% 0.009		
Lipids									
Total-C (mmol/L)		15	1,673	-0.20 [-0.31, -0.10]	-1.05 [-1.59, -0.50]	-	<0.001 52% 0.01		
LDL-C (mmol/L)	Siervo et al.	13	1,673	-0.10 [-0.20, -0.01]	-0.59 [-1.13, -0.04]	-	0.03 37% 0.08		<b>@@@</b> O Moderate
HDL-C (mmol/L)	2015 [11]	15	1,749	-0.00 [-0.05, 0.05]	-0.02 [-0.38, 0.33]*	-	0.95 76% <0.001		
TG (mmol/L)		14	1,654	-0.00 [-0.06, 0.05]	-0.04 [-0.41, 0.33]	( +	0.87 0% 0.88		
Glycemic	control								
HbAlc (%)	conduct**	2	65	-0.53 [-0.62, -0.43]	-7.73 [-9.05, -6.27] —	← [	<0.001 99% <0.001		
Glucose (mmol/L)	Siervo et al. 2015 [11]	10	826	-0.19 [-0.39, 0.02]	-0.57 [-1.19, 0.05]	-	0.07 59% 0.008		
Insulin (uU/mL)	Shirani et al.	11	760	-0.15 [-0.22, -0.08]	-1.27 [-1.86, -0.68]	-	<0.001 0% 0.49		<b>⊕⊕⊕</b> ⊖ Moderate
HOMA-IR	2013 [66]	8	603	-0.05 [-0.15, 0.05]	-0.35 [-1.04, 0.35]	-	NA 16% 0.303		⊕⊕⊕⊖ Moderate
Body we	2016 [71]	11	1,211	-1.42 [-2.03, -0.82]	-1.39 [-1.98, -0.80]	+	<0.0001 71% <0.001		
Inflamma	ation	6	451	-3.90 [-9.33, 1.62]	-0.57 [-1.36, 0.24]	-	NA 97% <0.001		
					-10.00	-5.00 0.00	5.00		
						Benefit	Harm		

## MEDITERRANEAN DIET





Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

[Intervention Review]

# Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease

Karen Rees<sup>1</sup>, Andrea Takeda<sup>2</sup>, Nicole Martin<sup>2</sup>, Leila Ellis<sup>1</sup>, Dilini Wijesekara<sup>1</sup>, Abhinav Vepa<sup>1</sup>, Archik Das<sup>1</sup>, Louise Hartley<sup>3</sup>, Saverio Stranges<sup>4</sup>

<sup>1</sup>Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK. <sup>2</sup>Institute of Health Informatics Research, University College London, London, UK. <sup>3</sup>RTI Health Solutions, Manchester, UK. <sup>4</sup>Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Canada



- High intake of vegetables and fruit
- Whole grain breads
- Beans
- Nuts and seeds
- Olive oil as main source of fat
- Low to moderate amounts of dairy
- Low quantities of red meat
- Higher quantities of fish
- Moderate wine consumption





#### Primary outcomes

- 1. Cardiovascular mortality.
- 2. All-cause mortality.



 Non-fatal endpoints such as MI, CABG, PTCA, angina or angiographically defined CHD, stroke, carotid endarterectomy or peripheral arterial disease (PAD).

#### Secondary outcomes

- Changes in blood lipids (total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides) and blood pressure (systolic and diastolic blood pressure).
- 2. Occurrence of type 2 diabetes as a major CVD risk factor.
- 3. Health-related quality of life.
- 4. Adverse effects (as defined by the authors of the included trials).
- 5. Costs.


#### AUTHORS' CONCLUSIONS

#### Implications for practice

Despite the large number of trials included in the review there is still uncertainty regarding the effects of a Mediterranean-style diet on clinical endpoints and cardiovascular disease (CVD) risk factors for both primary and secondary prevention from current clinical trial evidence. However, based on supportive observational evidence, positive findings from early clinical trials and the biological plausibility of several mechanisms to explain the beneficial effect of the Mediterranean diet, it has become a popular dietary pattern.

### compliance

Compliance to Medication, Diet and Exercise





### Take Home message

- ✓ The rehabilitation patients differ in risk factors
- ✓ Different diets have diverse effects on the components of cardiometabolic risk factors
- There is a great importance in personal dietary evaluation and treatment
- Motivation for change is a major factor in choosing the right diet regime

# טוב לדאוג לחולה שיהיה בריא, אבל יותר " טוב לדאוג לבריא שלא יחלה"(היפוקרטס)